DiaMedica Therapeutics (DMAC) Total Debt (2017)

DiaMedica Therapeutics (DMAC) reported Total Debt of $84000.0 for Q4 2017.

DiaMedica Therapeutics (DMAC) Total Debt (2017) Analysis & Trends

DiaMedica Therapeutics has reported Total Debt for 1 years, with the latest figure at $84000.0 in Q4 2017.

  • For the quarter ending Q4 2017, Total Debt changed N/A year-over-year to $84000.0; the trailing twelve-month figure through Dec 2017 stood at $84000.0 (changed N/A YoY), and the FY2017 full-year result was $84000.0, changed N/A from the prior year.
  • Total Debt for Q4 2017 stood at $84000.0.
  • The five-year high for Total Debt was $84000.0 in Q4 2017, with the low at $84000.0 in Q4 2017.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Total Debt (Qtr)
1 Alterity Therapeutics 762,369.55 Bn 762,369.51 Bn - -
2 Belite Bio 55,096.00 Bn 55,096.00 Bn - -
3 Quantum Biopharma 17,755.80 Bn 17,755.79 Bn - -
4 Legend Biotech 3,486.00 Bn 3,485.71 Bn 242.10 Mn 319.10 Mn
5 Akari Therapeutics 1,737.42 Bn 1,737.41 Bn - -
6 Evaxion A 1,551.28 Bn 1,551.26 Bn - -
7 Psyence Biomedical 227.32 Bn 227.31 Bn - -
8 Vertex Pharmaceuticals 110.84 Bn 103.59 Bn 2.59 Bn -
9 Abivax 91.71 Bn 91.71 Bn - -
10 DiaMedica Therapeutics 285.11 Mn 233.77 Mn - -

Historic Data

Download Data
DateValue
Dec 31, 2017 84,000.00